165 related articles for article (PubMed ID: 11939411)
1. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
2. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956.
Nagasu T; Yoshimatsu K; Rowell C; Lewis MD; Garcia AM
Cancer Res; 1995 Nov; 55(22):5310-4. PubMed ID: 7585593
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
[TBL] [Abstract][Full Text] [Related]
6. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
8. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
10. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
[TBL] [Abstract][Full Text] [Related]
11. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
End DW; Smets G; Todd AV; Applegate TL; Fuery CJ; Angibaud P; Venet M; Sanz G; Poignet H; Skrzat S; Devine A; Wouters W; Bowden C
Cancer Res; 2001 Jan; 61(1):131-7. PubMed ID: 11196150
[TBL] [Abstract][Full Text] [Related]
13. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
Omer CA; Chen Z; Diehl RE; Conner MW; Chen HY; Trumbauer ME; Gopal-Truter S; Seeburger G; Bhimnathwala H; Abrams MT; Davide JP; Ellis MS; Gibbs JB; Greenberg I; Koblan KS; Kral AM; Liu D; Lobell RB; Miller PJ; Mosser SD; O'Neill TJ; Rands E; Schaber MD; Senderak ET; Oliff A; Kohl NE
Cancer Res; 2000 May; 60(10):2680-8. PubMed ID: 10825141
[TBL] [Abstract][Full Text] [Related]
14. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor.
Ito T; Kawata S; Tamura S; Igura T; Nagase T; Miyagawa JI; Yamazaki E; Ishiguro H; Matasuzawa Y
Jpn J Cancer Res; 1996 Feb; 87(2):113-6. PubMed ID: 8609057
[TBL] [Abstract][Full Text] [Related]
15. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
Aklilu F; Park M; Goltzman D; Rabbani SA
Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
17. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Moasser MM; Sepp-Lorenzino L; Kohl NE; Oliff A; Balog A; Su DS; Danishefsky SJ; Rosen N
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1369-74. PubMed ID: 9465021
[TBL] [Abstract][Full Text] [Related]
18. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
20. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]